{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T23:21:06Z","timestamp":1790983266216,"version":"4.1.0"},"reference-count":119,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seminarsinnephrology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nephrology"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.semnephrol.2018.10.002","type":"journal-article","created":{"date-parts":[[2018,12,31]],"date-time":"2018-12-31T03:02:23Z","timestamp":1546225343000},"page":"17-30","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":67,"title":["Epidemiology, Pathophysiology, and Management of Hepatorenal Syndrome"],"prefix":"10.1016","volume":"39","author":[{"given":"Ahmed Adel","family":"Amin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eman Ibrahim","family":"Alabsawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajiv","family":"Jalan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Davenport","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semnephrol.2018.10.002_bib0001","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.jhep.2014.12.029","article-title":"Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites","volume":"62","author":"Angeli","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0002","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13613-017-0249-6","article-title":"Prognosis of cirrhotic patients admitted to intensive care unit: a meta-analysis","volume":"7","author":"Weil","year":"2017","journal-title":"Ann Intensive Care"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0003","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(03)14903-3","article-title":"Hepatorenal syndrome","volume":"362","author":"Gines","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0004","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1099\/jmm.0.2008\/001867-0","article-title":"Bacterial DNA and its consequences in patients with cirrhosis and culture-negative, non-neutrocytic ascites","volume":"57","author":"El-Naggar","year":"2008","journal-title":"J Med Microbiol"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0005","doi-asserted-by":"crossref","first-page":"32341","DOI":"10.1038\/srep32341","article-title":"Characterization of inflammatory response in acute-on-chronic liver failure and relationship with prognosis","volume":"6","author":"Sol\u00e9","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0006","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1136\/gut.2009.180570","article-title":"Low cardiac output predicts development of hepatorenal syndrome and survival in patients with cirrhosis and ascites","volume":"59","author":"Krag","year":"2010","journal-title":"Gut"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0007","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/hep.510290203","article-title":"Effect of losartan, an angiotensin II receptor antagonist, on portal pressure in cirrhosis","volume":"29","author":"Schneider","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0008","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1136\/gut.2006.107789","article-title":"Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis","volume":"84","author":"Salerno","year":"2007","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0009","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1136\/gut.2010.236133","article-title":"Working Party proposal for a revised classification system of renal dysfunction in patients with cirrhosis","volume":"60","author":"Wong","year":"2011","journal-title":"Gut"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0010","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.kint.2017.04.048","article-title":"Acute kidney injury in acute-on-chronic liver failure: where does hepatorenal syndrome fit?","volume":"92","author":"Davenport","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0011","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1053\/j.gastro.2013.02.042","article-title":"Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis","volume":"144","author":"Moreau","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0012","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1053\/j.gastro.2014.05.005","article-title":"Toward an improved definition of acute-on-chronic liver failure","volume":"147","author":"Jalan","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0013","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1053\/j.gastro.2016.02.026","article-title":"Terlipressin plus albumin is more effective than albumin alone in improving renal function in patients with cirrhosis and hepatorenal syndrome type 1","volume":"150","author":"Boyer","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0014","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.cgh.2016.07.016","article-title":"Terlipressin improves renal function and reverses hepatorenal syndrome in patients with systemic inflammatory response syndrome","volume":"15","author":"Wong","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0015","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.jhep.2013.03.039","article-title":"Evaluation of the Acute Kidney Injury Network criteria in hospitalized patients with cirrhosis and ascites","volume":"59","author":"Piano","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0016","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1002\/hep.22605","article-title":"Acute kidney injury in cirrhosis","volume":"48","author":"Garcia-Tsao","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0017","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1093\/ndt\/gfm914","article-title":"Outcome predictors and new score of critically ill cirrhotic patients with acute renal failure","volume":"23","author":"Fang","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0018","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.3748\/wjg.v18.i24.3035","article-title":"Kidneys in chronic liver diseases","volume":"18","author":"Hartleb","year":"2012","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0019","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1002\/hep.25735","article-title":"Association of AKI with mortality and complications in hospitalized patients with cirrhosis","volume":"57","author":"Belcher","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0020","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1136\/flgastro-2012-100291","article-title":"Acute kidney injury is independently associated with death in patients with cirrhosis","volume":"4","author":"Scott","year":"2013","journal-title":"Frontline Gastroenterol"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0021","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.jhep.2011.10.016","article-title":"Renal failure and cirrhosis: a systematic review of mortality and prognosis","volume":"56","author":"Fede","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0022","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jhep.2005.10.013","article-title":"Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies","volume":"44","author":"D'Amico","year":"2006","journal-title":"J Hepatol"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0023","first-page":"1310","article-title":"Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis","volume":"56","author":"Salerno","year":"2007","journal-title":"Gut"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0024","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.jhep.2009.11.025","article-title":"The evaluation of renal function and disease in patients with cirrhosis","volume":"52","author":"Francoz","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/cc5713","article-title":"Acute kidney injury network: report of an initiative to improve outcomes in acute kidney injury","volume":"11","author":"Mehta","year":"2007","journal-title":"Crit Care"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0026","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1136\/gutjnl-2011-301255","article-title":"Acute kidney injury in decompensated cirrhosis","volume":"62","author":"Tsien","year":"2013","journal-title":"Gut"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0027","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.jhep.2013.04.036","article-title":"A modified acute kidney injury classification for diagnosis and risk stratification of impairment of kidney function in cirrhosis","volume":"59","author":"Fagundes","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0028","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1056\/NEJM199808203390807","article-title":"Nitric oxide as a mediator of hemodynamic abnormalities and sodium and water retention in cirrhosis","volume":"339","author":"Martin","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0029","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1056\/NEJMra0809139","article-title":", Gin\u00e8s P. Renal failure in cirrhosis","volume":"361","author":"Gines","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0030","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.jhep.2010.08.001","article-title":"Renal and circulatory dysfunction in cirrhosis: current management and future perspectives","volume":"53","author":"Sol\u00e0","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0031","first-page":"1408","article-title":"The role of duplex-doppler ultrasonography in the diagnosis of renal dysfunction and hepatorenal syndrome in patients with liver cirrhosis","volume":"51","author":"Kastelan","year":"2004","journal-title":"Hepatogastroenterology"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0032","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1056\/NEJM196906192802501","article-title":"Transplantation of cadaveric kidneys from patients with hepatorenal syndrome\u2014evidence for the functional nature of renal failure in advanced liver disease","volume":"280","author":"Koppel","year":"1969","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0033","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1056\/NEJM197311292892201","article-title":"Recovery from \u201chepatorenal syndrome\u201d after orthotopic liver transplantation","volume":"289","author":"Iwatsuki","year":"1973","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0034","doi-asserted-by":"crossref","unstructured":"Kalambokis GN, Tsiakas I, Christaki M, et al. Systemic hemodynamic response to terlipressin predicts development of hepatorenal syndrome and survival in advanced cirrhosis. Eur J Gastroenterol Hepatol. 2018;30:659-67.","DOI":"10.1097\/MEG.0000000000001088"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0035","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s12876-015-0389-9","article-title":"Albumin treatment regimen for type 1 hepatorenal syndrome: a dose-response meta-analysis","volume":"15","author":"Salerno","year":"2015","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0036","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1111\/j.1365-2036.2006.03086.x","article-title":"Meta-analysis: terlipressin therapy for the hepatorenal syndrome","volume":"24","author":"Fabrizi","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0037","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1002\/hep.23775","article-title":"Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites","volume":"52","author":"Serst\u00e9","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0038","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1053\/j.gastro.2014.03.005","article-title":"Nonselective \u03b2 blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis","volume":"146","author":"Mandorfer","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0039","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1002\/hep.26535","article-title":"Relative adrenal insufficiency in decompensated cirrhosis: relationship to short-term risk of severe sepsis, hepatorenal syndrome, and death","volume":"58","author":"Acevedo","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0040","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1111\/j.1478-3231.2011.02751.x","article-title":"Cardiac dysfunction in cirrhosis \u2013 does adrenal function play a role? A hypothesis","volume":"32","author":"Theocharidou","year":"2012","journal-title":"Liver Int"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0041","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1055\/s-0036-1583194","article-title":"The organs in acute-on-chronic liver failure","volume":"36","author":"Weichselbaum","year":"2016","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0042","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1002\/hep.21920","article-title":"Model for end-stage liver disease score and systemic inflammatory response are major prognostic factors in patients with cirrhosis and acute functional renal failure","volume":"46","author":"Thabut","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0043","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/hep.510270507","article-title":"Tumor necrosis factor and interleukin-6 in spontaneous bacterial peritonitis in cirrhosis: relationship with the development of renal impairment and mortality","volume":"27","author":"Navasa","year":"1998","journal-title":"Hepatology"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0044","doi-asserted-by":"crossref","first-page":"R23","DOI":"10.1186\/cc11188","article-title":"Hepatorenal syndrome: the 8th International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group","volume":"16","author":"Nadim","year":"2012","journal-title":"Crit Care"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0045","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.jhep.2013.12.032","article-title":"Terlipressin and albumin for type-1 hepatorenal syndrome associated with sepsis","volume":"60","author":"Rodr\u00edguez","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0046","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1002\/hep.26687","article-title":"Type-1 hepatorenal syndrome associated with infections in cirrhosis: natural history, outcome of kidney function, and survival","volume":"59","author":"Barreto","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0047","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1002\/hep.28740","article-title":"Systemic inflammation in decompensated cirrhosis: characterization and role in acute-on-chronic liver failure","volume":"64","author":"Cl\u00e0ria","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0048","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1111\/j.1478-3231.2009.02182.x","article-title":"The spectrum of renal lesions in patients with cirrhosis: a clinicopathological study","volume":"30","author":"Trawale","year":"2010","journal-title":"Liver Int"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0049","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.jhep.2011.11.024","article-title":"Prevention of acute kidney injury in a rodent model of cirrhosis following selective gut decontamination is associated with reduced renal TLR4 expression","volume":"56","author":"Shah","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0050","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1159\/000064280","article-title":"Inflammatory cytokines and lipopolysaccharide induce fas-mediated apoptosis in renal tubular cells","volume":"91","author":"Jo","year":"2002","journal-title":"Nephron"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0051","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1053\/j.gastro.2007.06.065","article-title":"Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis","volume":"133","author":"Fern\u00e1ndez","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0052","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1007\/s10620-016-4313-0","article-title":"Rifaximin decreases the incidence and severity of acute kidney injury and hepatorenal syndrome in cirrhosis","volume":"61","author":"Dong","year":"2016","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0053","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2018.01.035","article-title":"Association between grade of acute on chronic liver failure and response to terlipressin and albumin in patients with hepatorenal syndrome","author":"Piano","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0054","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/ki.2013.78","article-title":"Bile cast nephropathy is a common pathologic finding for kidney injury associated with severe liver dysfunction","volume":"84","author":"Van Slambrouck","year":"2013","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0055","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jhep.2017.02.019","article-title":"Norursodeoxycholic acid ameliorates cholemic nephropathy in bile duct ligated mice","volume":"67","author":"Krones","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0056","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1111\/liv.12559","article-title":"Systemic inflammation is associated with increased intrahepatic resistance and mortality in alcohol-related acute-on-chronic liver failure","volume":"35","author":"Mehta","year":"2015","journal-title":"Liver Int"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0057","doi-asserted-by":"crossref","first-page":"433","DOI":"10.4254\/wjh.v5.i8.433","article-title":"Can non-invasive measurements aid clinical assessment of volume in patients with cirrhosis?","volume":"5","author":"Davenport","year":"2013","journal-title":"World J Hepatol"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0058","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1186\/s13054-016-1478-z","article-title":"Acute kidney injury 2016: diagnosis and diagnostic workup","volume":"20","author":"Ostermann","year":"2016","journal-title":"Crit Care"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0059","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1373\/clinchem.2008.116863","article-title":"Prime time for enzymatic creatinine methods in pediatrics","volume":"55","author":"Cobbaert","year":"2009","journal-title":"Clin Chem"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0060","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1046\/j.1523-1755.2002.00683.x","article-title":"Significance of the fractional excretion of urea in the differential diagnosis of acute renal failure","volume":"62","author":"Carvounis","year":"2002","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0061","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/hep.29772","article-title":"Fractional excretion of urea: a simple tool for the differential diagnosis of acute kidney injury in cirrhosis","volume":"68","author":"Patidar","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0062","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1681\/ASN.2006101108","article-title":"Urea and renal function in the 21st century: insights from knockout mice","volume":"18","author":"Fenton","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0063","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMra054415","article-title":"Assessing kidney function\u2014measured and estimated glomerular filtration rate","volume":"354","author":"Stevens","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0064","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1111\/jgh.13983","article-title":"Serum cystatin C level: an excellent predictor of mortality in patients with cirrhotic ascites","volume":"33","author":"Seo","year":"2018","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0065","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/hep.26980","article-title":"Kidney biomarkers and differential diagnosis of patients with cirrhosis and acute kidney injury","volume":"60","author":"Belcher","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0066","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1515\/cclm-2017-0483","article-title":"Circulating miR-21, miR-210 and miR-146a as potential biomarkers to differentiate acute tubular necrosis from hepatorenal syndrome in patients with liver cirrhosis: a pilot study","volume":"56","author":"Watany","year":"2018","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0067","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.jhep.2014.12.029","article-title":"Erratum: diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites","volume":"62","author":"Angeli","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0068","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/hep.28891","article-title":"Development and validation of a mathematical equation to estimate glomerular filtration rate in cirrhosis: the royal free hospital cirrhosis glomerular filtration rate","volume":"65","author":"Kalafateli","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0069","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1007\/s12072-017-9815-0","article-title":"Management of ascites and hepatorenal syndrome","volume":"12 Suppl 1","author":"Piano","year":"2018","journal-title":"Hepatol Int"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0070","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1378\/chest.07-2331","article-title":"Does central venous pressure predict fluid responsiveness? A systematic review of the literature and the tale of seven mares","volume":"134","author":"Marik","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0071","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1001\/jama.2013.430","article-title":"Association of hydroxyethyl starch administration with mortality and acute kidney injury in critically ill patients requiring volume resuscitation: a systematic review and meta-analysis","volume":"309","author":"Zarychanski","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0072","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1056\/NEJMoa1209759","article-title":"Hydroxyethyl starch or saline for fluid resuscitation in intensive care","volume":"367","author":"Myburgh","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0073","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1080\/17474124.2018.1417034","article-title":"Hepatorenal syndrome: the clinical impact of vasoactive therapy","volume":"12","author":"Colle","year":"2018","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0074","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.jhep.2014.04.012","article-title":"Human serum albumin, systemic inflammation, and cirrhosis","volume":"61","author":"Arroyo","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0075","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.jhep.2010.05.004","article-title":"EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis","volume":"53","author":"Gin\u00e8s","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0076","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/apt.13912","article-title":"Systematic review with meta-analysis: vasoactive drugs for the treatment of hepatorenal syndrome type 1","volume":"45","author":"Gifford","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0077","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1002\/hep.510270206","article-title":"Effects of F-180, a new selective vasoconstrictor peptide, compared with terlipressin and vasopressin on systemic and splanchnic hemodynamics in a rat model of portal hypertension","volume":"27","author":"Bernadich","year":"1998","journal-title":"Hepatology"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0078","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/jgh.14009","article-title":"Terlipressin: current and emerging indications in chronic liver disease","volume":"33","author":"Papaluca","year":"2018","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0079","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1111\/apt.14052","article-title":"Reversal of hepatorenal syndrome type 1 with terlipressin plus albumin vs. placebo plus albumin in a pooled analysis of the OT-0401 and REVERSE randomised clinical studies","volume":"45","author":"Sanyal","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0080","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/S2468-1253(16)30157-1","article-title":"Comparative efficacy of pharmacological strategies for management of type 1 hepatorenal syndrome: a systematic review and network meta-analysis","volume":"2","author":"Facciorusso","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0081","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s11606-017-4178-8","article-title":"Vasoactive agents for hepatorenal syndrome: a mixed treatment comparison network meta-analysis and trial sequential analysis of randomized clinical trials","volume":"33","author":"Sridharan","year":"2018","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0082","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1080\/17474124.2017.1356223","article-title":"Comparative efficacy of vasoconstrictor therapies for type 1 hepatorenal syndrome: a network meta-analysis","volume":"11","author":"Zheng","year":"2017","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0083","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/MCG.0000000000000913","article-title":"Pharmacological therapies for hepatorenal syndrome","volume":"52","author":"Nanda","year":"2018","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0084","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1159\/000355739","article-title":"Hepatorenal syndrome and novel advances in its management","volume":"37","author":"Fabrizi","year":"2013","journal-title":"Kidney Blood Press Res"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0085","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1002\/hep.28396","article-title":"Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome: a randomized controlled study","volume":"63","author":"Cavallin","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0086","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1002\/hep.27154","article-title":"Continuous outpatient terlipressin infusion for hepatorenal syndrome as a bridge to successful liver transplantation","volume":"60","author":"Robertson","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0087","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/hep.28325","article-title":"Efficacy of outpatient continuous terlipressin infusions for hepatorenal syndrome","volume":"64","author":"Vasudevan","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0088","doi-asserted-by":"crossref","first-page":"345","DOI":"10.4254\/wjh.v8.i7.345","article-title":"Human albumin solution for patients with cirrhosis and acute on chronic liver failure: beyond simple volume expansion","volume":"8","author":"Valerio","year":"2016","journal-title":"World J Hepatol"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0089","doi-asserted-by":"crossref","first-page":"293","DOI":"10.4254\/wjh.v9.i6.293","article-title":"Hepatorenal syndrome: update on diagnosis and therapy","volume":"9","author":"Acevedo","year":"2017","journal-title":"World J Hepatol"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0090","first-page":"556","article-title":"Acute kidney dysfunction secondary to the abdominal compartment syndrome","volume":"19","author":"Shear","year":"2006","journal-title":"J Nephrol"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0091","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s00134-007-0969-4","article-title":"Intra-abdominal hypertension and acute renal failure in critically ill patients","volume":"34","author":"Dalfino","year":"2008","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0092","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/s00134-008-1253-y","article-title":"Renal resistive index and renal function before and after paracentesis in patients with hepatorenal syndrome and tense ascites","volume":"35","author":"Umgelter","year":"2009","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0093","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1097\/00000658-198810000-00012","article-title":"Manipulation of ascitic fluid pressure in cirrhotics to optimize hemodynamic and renal function","volume":"208","author":"Savino","year":"1988","journal-title":"Ann Surg"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0094","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1093\/ndt\/gfr736","article-title":"Medical management of hepatorenal syndrome","volume":"27","author":"Davenport","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0095","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1002\/lt.22395","article-title":"Impact of liver transplantation on the survival of patients treated for hepatorenal syndrome type 1","volume":"17","author":"Boyer","year":"2011","journal-title":"Liver Transpl"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0096","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/lt.21149","article-title":"Hepatorenal syndrome: a proposal for kidney after liver transplantation (KALT)","volume":"13","author":"Ruiz","year":"2007","journal-title":"Liver Transpl"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0097","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1002\/lt.24049","article-title":"Outcomes of patients with cirrhosis and hepatorenal syndrome type 1 treated with liver transplantation","volume":"21","author":"Wong","year":"2015","journal-title":"Liver Transpl"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0098","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/hepr.12764","article-title":"Influence of hepatorenal syndrome on outcome of living donor liver transplantation: a single-center experience in 357 patients","volume":"47","author":"Okamura","year":"2017","journal-title":"Hepatol Res"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0099","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.jcrc.2015.05.006","article-title":"Role of renal replacement therapy in patients with type 1 hepatorenal syndrome receiving combination treatment of vasoconstrictor plus albumin","volume":"30","author":"Zhang","year":"2015","journal-title":"J Crit Care"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0100","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.jhep.2013.06.014","article-title":"TIPS: 25 years later","volume":"59","author":"Rossle","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0101","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S1665-2681(19)31677-1","article-title":"Effects of TIPS on global end-diastolic volume and cardiac output and renal resistive index in ICU patients with advanced alcoholic cirrhosis","volume":"9","author":"Umgelter","year":"2010","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0102","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.dld.2018.01.123","article-title":"Transjugular intrahepatic portosystemic shunt for hepatorenal syndrome: a systematic review and meta-analysis","volume":"50","author":"Song","year":"2018","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0103","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002248","article-title":"Serelaxin as a potential treatment for renal dysfunction in cirrhosis: preclinical evaluation and results of a randomized phase 2 trial","volume":"14","author":"Snowdon","year":"2017","journal-title":"PLoS Med"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0104","doi-asserted-by":"crossref","first-page":"880","DOI":"10.3889\/oamjms.2017.173","article-title":"Protective effects of the third generation vasodilatory \u03b2eta - blocker nebivolol against D-galactosamine - induced hepatorenal syndrome in rats","volume":"5","author":"Atwa","year":"2017","journal-title":"Open Access Maced J Med Sci"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0105","doi-asserted-by":"crossref","first-page":"288","DOI":"10.5604\/01.3001.0010.8661","article-title":"Treatment of type-1 hepatorenal syndrome with pentoxifylline: a randomized placebo controlled clinical trial","volume":"17","author":"Stine","year":"2018","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0106","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1097\/MEG.0000000000000967","article-title":"Long-term rifaximin therapy as a primary prevention of hepatorenal syndrome","volume":"29","author":"Ibrahim","year":"2017","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0107","doi-asserted-by":"crossref","first-page":"e187","DOI":"10.1038\/ctg.2016.44","article-title":"Rifaximin exerts beneficial effects independent of its ability to alter microbiota composition","volume":"7","author":"Kang","year":"2016","journal-title":"Clin Transl Gastroenterol"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0108","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1046\/j.1440-1746.2003.02934.x","article-title":"Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial","volume":"18","author":"Solanki","year":"2003","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0109","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1007\/s10620-007-9919-9","article-title":"Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome","volume":"53","author":"Neri","year":"2008","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0110","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1053\/j.gastro.2008.02.014","article-title":"A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome","volume":"134","author":"Sanyal","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0111","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1053\/j.gastro.2008.02.024","article-title":"Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study","volume":"134","author":"Mart\u00edn-Llah\u00ed","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0112","doi-asserted-by":"crossref","first-page":"S175","DOI":"10.14309\/00000434-201210001-00418","article-title":"Role of terlipressin and albumin combination versus albumin alone in hepatorenal syndrome","volume":"107","author":"Zafar","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0113","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.jhep.2007.04.010","article-title":"Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study","volume":"47","author":"Alessandria","year":"2007","journal-title":"J Hepatol"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0114","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1111\/liv.12179","article-title":"Noradrenaline vs terlipressin in the treatment of type 2 hepatorenal syndrome: a randomized pilot study","volume":"33","author":"Ghosh","year":"2013","journal-title":"Liver Int"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0115","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1111\/j.1572-0241.2008.01828.x","article-title":"An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response","volume":"103","author":"Sharma","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0116","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.jhep.2012.01.012","article-title":"Noradrenaline vs. terlipressin in the treatment of hepatorenal syndrome: a randomized study","volume":"56","author":"Singh","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0117","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/hep.27709","article-title":"Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: a randomized trial","volume":"62","author":"Cavallin","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0118","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jceh.2015.08.003","article-title":"Randomized controlled trial comparing the efficacy of terlipressin and albumin with a combination of concurrent dopamine, furosemide, and albumin in hepatorenal syndrome","volume":"5","author":"Srivastava","year":"2015","journal-title":"J Clin Exp Hepatol"},{"key":"10.1016\/j.semnephrol.2018.10.002_bib0119","first-page":"764","article-title":"Noradrenalin versus the combination of midodrine and octreotide in patients with hepatorenal syndrome: randomized clinical trial","volume":"3","author":"Tavakkoli","year":"2012","journal-title":"Int J Prev Med"}],"container-title":["Seminars in Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929518301530?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929518301530?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T23:32:28Z","timestamp":1759447948000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0270929518301530"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":119,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["S0270929518301530"],"URL":"https:\/\/doi.org\/10.1016\/j.semnephrol.2018.10.002","relation":{},"ISSN":["0270-9295"],"issn-type":[{"value":"0270-9295","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Epidemiology, Pathophysiology, and Management of Hepatorenal Syndrome","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nephrology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semnephrol.2018.10.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}